Mouthwash May Defeat COVID-19
Certain oral antiseptics and mouthwashes may have the ability to inactivate human coronaviruses, according to a Penn State College of Medicine research study.
This new study’s results published by the Journal of Infectious Diseases indicate that some of these products might be useful for reducing the viral load, or amount of virus, in the mouth after infection.
Furthermore, these mouthwash products may help to reduce the spread of SARS-CoV-2, the coronavirus that causes COVID-19.
These Penn State researchers concluded by saying ‘several formulations with significant SARS-CoV-2 inactivating properties in vitro support the idea that oral rinsing might reduce the viral load of saliva and could thus lower the transmission of SARS-CoV-2.’
Craig Meyers, MS, Ph.D., distinguished professor of microbiology and immunology and obstetrics and gynecology, led a group of physicians and scientists who tested several oral and nasopharyngeal rinses in a laboratory setting for their ability to inactivate human coronaviruses, which are similar in structure to SARS-CoV-2.
The products evaluated include a 1% solution of baby shampoo, a neti pot, peroxide sore-mouth cleansers, and mouthwashes.
The researchers found that several of the nasal and oral rinses had a strong ability to neutralize human coronavirus, which suggests that these products may have the potential to reduce the amount of virus spread by people who are COVID-19-positive.
“While we wait for a vaccine to be developed, methods to reduce transmission are needed,” Dr. Meyers said in a released press release. “The products we tested are readily available and often already part of people’s daily routines.”
Meyers and colleagues used a test to replicate the interaction of the virus in the nasal and oral cavities with the rinses and mouthwashes. Nasal and oral cavities are major points of entry and transmission for human coronaviruses.
They treated solutions containing a strain of human coronavirus, which served as a readily available and genetically similar alternative for SARS-CoV-2, with the baby shampoo solutions, various peroxide antiseptic rinses, and various brands of mouthwash.
They allowed the solutions to interact with the virus for 30 seconds, one minute, and two minutes, before diluting the solutions to prevent further virus inactivation.
According to Meyers, the outer envelopes of the human coronavirus tested and SARS-CoV-2 are genetically similar so the research team hypothesizes that a similar amount of SARS-CoV-2 may be inactivated upon exposure to the solution.
To measure how much virus was inactivated, the researchers placed the diluted solutions in contact with cultured human cells. They counted how many cells remained alive after a few days of exposure to the viral solution and used that number to calculate the amount of human coronavirus that was inactivated as a result of exposure to the mouthwash or oral rinse that was tested.
The 1% baby shampoo solution, which is often used by head and neck doctors to rinse the sinuses, inactivated greater than 99.9% of human coronavirus after a 2-minute contact time.
Several of the mouthwash and gargle products also were effective at inactivating the infectious virus. Many inactivated greater than 99.9% of the coronavirus after only 30-seconds of contact time and some inactivated 99.99% of the virus after 30-seconds.
According to Meyers, the results with mouthwashes are promising and add to the findings of a study showing that certain types of oral rinses could inactivate SARS-CoV-2 in similar experimental conditions.
In addition to evaluating the solutions at longer contact times, they studied over-the-counter products and nasal rinses that were not evaluated in the other study. Meyers said the next step to expand upon these results is to design and conduct clinical trials that evaluate whether products like mouthwashes can effectively reduce viral load in COVID-19-positive patients.
“People who test positive for COVID-19 and return home to quarantine may possibly transmit the virus to those they live with,” said Meyers.
“Clinical trials are needed to determine if these products can reduce the amount of virus COVID-positive patients or those with high-risk occupations may spread while talking, coughing, or sneezing. Even if the use of these solutions could reduce transmission by 50%, it would have a major impact.”
Janice Milici, Samina Alam, David Quillen, David Goldenberg, and Rena Kass of Penn State College of Medicine and Richard Robison of Brigham Young University also contributed to this research. The research was supported by funds from Penn State Huck Institutes for the Life Sciences. The researchers declare no conflict of interest.
CoronavrisToday publishes research-based news.